Clusterin and Chemoresistance in Pancreatic Cancer
Author Information
Author(s): Chen Qingfeng, Wang Zhengkun, Zhang Kejun, Liu Xiaoyi, Cao Weihong, Zhang Lei, Zhang Shuhua, Yan Bomin, Wang Yaoguang, Xia Chunping
Primary Institution: Affiliated Hospital of Medical College, QingDao University
Hypothesis
Does clusterin confer gmcitabine resistance in pancreatic cancer cells?
Conclusion
Clusterin expression is significantly higher in pancreatic cancer tissues than in normal tissues, suggesting it may confer gmcitabine resistance.
Supporting Evidence
- Clusterin expression was significantly higher in pancreatic cancer tissues compared to normal tissues.
- Clusterin levels correlated with gmcitabine resistance in pancreatic cancer cell lines.
- Treatment with antisense oligonucleotide against clusterin reduced gmcitabine resistance.
Takeaway
Clusterin is a protein that helps pancreatic cancer cells resist a common drug called gmcitabine, and reducing clusterin can make the cancer cells more sensitive to the drug.
Methodology
Immunohistochemistry, Western blot, RT-PCR, and MTT assays were used to evaluate clusterin expression and its effect on gmcitabine resistance in pancreatic cancer tissues and cell lines.
Limitations
The study primarily focused on a limited number of pancreatic cancer cell lines and may not represent all pancreatic cancer types.
Participant Demographics
50 pancreatic cancer tissues and 25 matched background tissues were analyzed.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website